Abstract: The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.

Abstract: Provided are compositions and methods for use in selectively killing certain types of bacteria which include: C. perfringens, C. sordelli and C. histolyticum. The compositions include lysin PlyCP025, as well as catalytically active fragments thereof, and variants thereof that retain killing activity. Methods for reducing one or more of C. perfringens, C. sordelli or C. histolyticum bacteria are provide and involve contacting such bacteria with a composition that contains PlyCP025 or an enzymatically active fragment or variant thereof, which can be provided as recombinant polypeptides. The composition and methods are useful for human and veterinary purposes. In certain examples, the compositions and methods are used to treat bacteria that infect avian animals. Pharmaceutical formulations containing the polypeptides are provided, as are methods of making the polypeptides using expression vectors. The expression vectors, and cells containing them are included.

Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

Abstract: Provided are compositions and methods for use in selectively killing one or more of C. perfringens, C. sordelli and C. histolyticum. The compositions include lysin PlyCP025, as well as catalytically active fragments thereof, and variants thereof that retain killing activity. Methods for reducing one or more of C. perfringens, C. sordelli or C. histolyticum bacteria are provide and involve contacting such bacteria with a composition that contains PlyCP025 or an enzymatically active fragment or variant thereof, which can be provided as recombinant polypeptides. The composition and methods are useful for human and veterinary purposes. Diagnostic approaches are also included by contacting a sample obtained or derived from an animal, with a recombinant polypeptide, and detecting binding of the polypeptide to bacteria in the sample if said bacteria that are bound to the polypeptide are present in the sample. The polypeptide may thus be detectably labeled to produce a detectable signal.

Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

Abstract: Provided are polypeptides and compositions comprising the polypeptides for use in killing and/or inhibiting growth of Gram-negative bacteria, particularly P. aeruginosa. The polypeptides are contiguous polypeptides (lysocins) that contain an engineered bacteriocin segment that can be translocated through an outer membrane channel of the Gram-negative bacteria, such as Domain I of the S-type poycin from P. aeruginosa bacterocin pyocin S2 (PyS2) linked to a lysin catalytic segment that has peptidoglycan (PG) hydrolase activity. The lysin catalytic segment can be a catalytic segment of GN4 lysin or any other lysin catalytic segment or a hydrolytic enzyme thereof that has PG hydrolase activity.

Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acintobacter lysin polypeptides.

Abstract: The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.

Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

Abstract: Provided are methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-negative bacteria, including Klebsiella, Enterobacter, and Pseudomonas, and related conditions. The compositions and methods utilize Klebsiellapneumonia, Enterobacter, and Pseudomonas derived bacteriophage lysins, and variants thereof, including truncations thereof.

Abstract: Provided are compositions and methods for use in selectively killing one or more of C. perfringens, C. sordelli and C. histolyticum. The compositions include lysin PlyCP025, as well as catalytically active fragments thereof, and variants thereof that retain killing activity. Methods for reducing one or more of C. perfringens, C. sordelli or C. histolyticum bacteria are provide and involve contacting such bacteria with a composition that contains PlyCP025 or an enzymatically active fragment or variant thereof, which can be provided as recombinant polypeptides. The composition and methods are useful for human and veterinary purposes. Diagnostic approaches are also included by contacting a sample obtained or derived from an animal, with a recombinant polypeptide, and detecting binding of the polypeptide to bacteria in the sample if said bacteria that are bound to the polypeptide are present in the sample. The polypeptide may thus be detectably labeled to produce a detectable signal.

Abstract: The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. aureus (MRSA) and vancomycin intermediate S. aureus (VISA).

Abstract: Provided are methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of Gram-negative bacteria, including Pseudomonas, and related conditions. Provided are compositions and methods incorporating and utilizing Pseudomonas aeruginosa derived bacteriophage lysins, and variants thereof, including truncations thereof. Methods for treatment of humans and non-human animals are provided.

Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of, gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.

Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acinetobacter lysin polypeptides.

Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.